Literature DB >> 2253793

Comparison of conservative surgery and radiotherapy with mastectomy in the treatment of early breast cancer.

Z Rayter1, J C Gazet, H T Ford, D F Easton, R C Coombes.   

Abstract

We have compared overall survival, and local and distant recurrence-free survival in patients with early breast cancer treated by mastectomy, with patients treated by wide local excision and radiotherapy. To do this, we reviewed a consecutive, unselected series of patients presenting with early breast cancer (T0-T2, N0-N1b, UICC) between 1973 and 1981 to one surgeon (J.-C.G.) and one radiotherapist (H.T.F.). The mean follow-up was 9 years (minimum 6 years, maximum 14 years). Only 9 patients received any adjuvant therapy. At 10 years the relapse-free survival was 65% for both groups of patients; the overall 10-year survival was 70% for patients treated by wide local excision and radiotherapy, and 67% for patients treated by mastectomy. The actuarial loco-regional recurrence rate at 10 years was 15% for patients treated by wide local excision and 13% for patients treated by mastectomy. There were no significant differences in overall survival, loco-regional and distant relapse-free survival between the two groups of patients. Our results support other reports that conservative surgery and radiotherapy in early breast cancer does not adversely affect long-term prognosis.

Entities:  

Mesh:

Year:  1990        PMID: 2253793

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  2 in total

1.  Other primary malignancies in breast cancer patients treated with breast conserving surgery and radiation therapy.

Authors:  Min Yi; Janice N Cormier; Yan Xing; Sharon Hermes Giordano; Christy Chai; Funda Meric-Bernstam; Georges Vlastos; Henry M Kuerer; Nadeem Q Mirza; Thomas A Buchholz; Kelly K Hunt
Journal:  Ann Surg Oncol       Date:  2012-12-06       Impact factor: 5.344

2.  Pain and other symptoms during the first year after radical and conservative surgery for breast cancer.

Authors:  T Tasmuth; K von Smitten; E Kalso
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.